Revolution Medicines CEO to Attend Upcoming Investor Events

Author: Logan Wright Updated: 03-31-2025 04:28 PM

Revolution Medicines Preparing for Notable Investor Conferences

As a leading oncology firm, Revolution Medicines, Inc. (NASDAQ: RVMD) is in the spotlight as it announces participation in two significant investor conferences. These events are an excellent opportunity for the company's leadership to connect with investors and present the advancements in their targeted cancer therapies.

Details of the Upcoming Conferences

Mark A. Goldsmith, M.D., Ph.D., serves as the chief executive officer and chairman of Revolution Medicines. His participation in these conferences will enhance insights into the company's innovative approaches. Here’s what you need to know about the two events:

Needham 24th Annual Virtual Healthcare Conference

This event will feature a fireside chat scheduled for Monday, April 7, at 2:15 p.m. ET. This is an opportunity for attendees to learn more about the strategic directions of Revolution Medicines and engage with its leadership.

Stifel 2025 Virtual Targeted Oncology Forum

The next event is the Stifel 2025 Virtual Targeted Oncology Forum, where Revolution Medicines will again showcase their expertise. This fireside chat will take place on Wednesday, April 9, at 1:00 p.m. ET. These discussions will underline the capital markets' interest in the company's unique therapies.

Accessing the Webcasts

Interested parties can tune into these sessions via live webcast. Additionally, recordings will be accessible after the events, providing convenient access for those who cannot attend live. For more details, visit the company’s official website.

About Revolution Medicines

Revolution Medicines specializes in developing groundbreaking therapies targeting RAS-addicted cancers. Their R&D pipeline includes cutting-edge RAS(ON) inhibitors, such as:

Daraxonrasib (RMC-6236) - a multi-selective inhibitor.
Elironrasib (RMC-6291) - focuses on G12C-selective mutations.
Zoldonrasib (RMC-9805) - designed for G12D-selective mutations.

Looking ahead, the company anticipates the clinical development of RMC-5127, aimed at G12V mutations, which will broaden their treatment capabilities. Additionally, the company is exploring other mutant-selective inhibitors, showcasing a comprehensive pipeline offering innovative treatment options for patients.

Connect with Revolution Medicines

For ongoing updates about their therapies and investor relations, individuals are encouraged to visit their website and follow their social media channels. Social platforms are a great way to stay informed about the latest news and advancements.

Revolution Medicines Media & Investor Contact

For media inquiries, contact: media@revmed.com

For investor relations, contact: investors@revmed.com

Frequently Asked Questions

What is Revolution Medicines, Inc. known for?

Revolution Medicines is focused on developing targeted therapies for treating RAS-addicted cancers, utilizing innovative research and development approaches.

When and where will the investor conferences take place?

The conferences will occur virtually, with specific dates for the fireside chats set for April 7 and April 9.

How can I access the webcasts of the events?

Webcasts can be accessed live during the events or through archived recordings on the company's official website following the events.

What are some products in Revolution Medicines’ pipeline?

The pipeline includes various RAS(ON) inhibitors focusing on different mutations, showcasing their commitment to advancing cancer treatment.

How can I stay updated with Revolution Medicines?

You can stay updated by visiting their official website and following them on social media for real-time information and press releases.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.